Lichen planus pigmentosus (LPP) is considered a rare variant of lichen planus (LP). It is characterized by acquired dark brown to gray macular pigmentation located on sunexposed areas of the face, neck, and flexures, commonly found in dark-skinned patients.
Introduction
Lichen planus pigmentosus (LPP) is considered to be a rare variant of lichen planus (LP) by most authors considering their similar immunopathogenesis and occasional coexistence in some patients. [1] [2] [3] It is characterized by chronic acquired dark brown to gray macular pigmentation with an unclear etiology and pathogenesis. It affects not only sun-exposed areas of the face and neck but also sun-protected flexural skin, such as the axillae and inguinal areas. It is common in middle-aged patients with dark skin and is rare in Caucasians. LPP causes emotional stress due to its aesthetic appearance and chronic nature. Moreover, it may be associated with other disorders such as hepatitis C virusinduced liver disease, endocrinopathies, and autoimmune diseases as well as other variants of LP and its sequelae.
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History
It is possible that LPP had been described in 1935 under the name "lichens atypiques ou invisible pigmentogenes" in the French literature 4 and as "lichen pigmentosus" in 1956 in the Japanese literature. 5 In 1957, during the First Central American
Congress of Dermatology, Oswaldo Ramirez described a group of patients from El Salvador with a new dermatosis characterized by "ashen macules" with no apparent cause, which he called ashy dermatosis "dermatitis cenicienta". 6 Subsequently, in 1974, Bhutani described a series of patients in India with similar pigmentation to that described by Ramirez, some of whom had other variants of lichen planus concomitantly. These pigmented macules exhibited histopathological findings similar to lichen planus, with epidermal vacuolization and a band-like lichenoid infiltrate, therefore, he suggested the name lichen planus pigmentosus. 7 Later in 1992, Vega et al. attempted to separate these two entities by reporting clinicopathological differences between ashy dermatosis and lichen planus pigmentosus. 8 More recently, Kanwar et al. conducted a large study in 124 patients with LPP, which included a detailed description of the entity. 1 
Current Nosological Status of Ashy Dermatosis and Lichen Planus Pigmentosus
Although ashy dermatosis and LPP are currently considered distinct entities with specific differences in epidemiology, pathogenesis, clinical presentation, histopathological findings, prognosis, and response to treatment, [1] [2] [3] overlap between these two conditions is frequently observed. Therefore, some authors consider them part of the same nosological spectrum of a unique entity, while others argue that they are different diseases. 7, 8 The presence of this controversy makes it difficult to strictly categorize between LPP and ashy dermatosis.
9
Epidemiology LPP predominantly affects patients with darker skin phototypes III to VI, with phototype IV being the most frequently affected. It has been commonly observed in India, Latin America, Asia, and Africa, and is rare in Caucasians. In the majority of patients, it presents between the 3rd and 5th decades of life, but it has been found in individuals 13-67 years of age. It is more common in females, except for one study from the Middle East where it was observed more frequently in men with hepatitis C virus.
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Pathogenesis and etiology 
Clinical presentation
LPP mainly affects the face and neck (Fig. 1) . On the face, it has a predilection for the temporal and preauricular areas, whereas on the neck it affects all sides (Fig. 2) . The arms are more frequently involved than the legs and trunk. Flexural areas are affected in 20% of cases, mainly the axillae, followed by the inframammary folds and the inguinal creases (Fig. 3) . It rarely affects the oral mucosa and scalp. LPP does not usually affect the palms, soles, and nails. [1] [2] [3] LPP is characterized by a symmetrical distribution of dark brown to gray or gray-blue, round or oval macules with irregular and poorly-defined borders, which eventually enlarge and coalesce. [1] [2] [3] Rarely, incipient LPP manifests as entirely erythematous macules which represent an active phase that rapidly resolves 16 ( Fig. 4) . Morphological variants described in order of frequency from highest to lowest are diffuse, 1-3 reticular, [1] [2] [3] blotchy, 1-3 perifollicular, [1] [2] [3] 19 and annular, 16 all of which may coexist in the same patient. Occasionally, LPP can present concomitantly with LP; therefore, it is not surprising that active or resolving LP lesions be found in patients with LPP. 1, 7 The lesions are usually asymptomatic but present with mild itching in 27-62% of patients. [1] [2] [3] Itching is considered a marker of activity and progression; it is present in the initial and active phase and disappears quickly with or without treatment. 2 Rarely, a burning sensation might be present. 1 Evolution is chronic and progressive with remissions and exacerbations. Most patients have LPP for 6 months to 3 years, but the course and duration are unpredictable.
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Lichen planus pigmentosus inversus (LPP-inversus) LPP-inversus was described in 2001 by Pock et al., defining it as a variant of LPP limited to intertriginous and flexural regions, sparing sun-exposed areas. 10 It predominantly affects women, mostly after 40 years, but has been described in individuals 15-82 years of age. LPP-inversus affects fair and dark skin, with a worldwide distribution. [10] [11] [12] [20] [21] [22] [23] [24] Its pathogenesis is similar to LPP, but in LPP-inversus a transition from papular LP to virus has also been associated with LPP-inversus. 23 Hormonal factors could be involved as it occurs in patients with frontal fibrosing alopecia, which tends to occur in women during perimenopause and postmenopause. 11, 20, 21 LPP-inversus affects flexural areas, mainly the axillae, groin, submammary folds, and antecubital and popliteal fossae; however, the inner wrist, gluteal cleft, auricular sulci, abdominal folds, lumbar back, and neck can also be involved. 10-12,20- In LPP-inversus, brown homogeneous areas that represent epidermal pigmentation have been described on dermoscopy in addition to gray-brown or gray-blue dots and globules that represent pigmentary incontinence and melanophages in the papillary dermis. These gray dots are initially grouped in a diffuse black pepper-like pattern, but with time, they converge to form reticular, linear, and cobblestone patterns. White dots are secondary to lack of pigmentation in the follicular openings, and the absence of pigment in skin furrows may be due to lack of exposure to friction (Fig. 7) . [40] [41] [42] [43] In a study of LPP associated with FFA, a dotted pattern was also found. A pseudonetwork pattern and telangiectasias were also found, particularly with facial involvement of LPP. Loss of facial vellus hairs, pigmentation of follicular openings and rhomboidal structures were described, likely because of greater follicular involvement in cases of combined LPP and FFA. 44 With Wood's light examination, usually there is no enhancement, due to predominance of dermal melanin (Fig. 8) . 
Differential diagnosis Comments
Idiopathic eruptive macular pigmentation 9 Occurs in younger patients, usually ages 10-30. Brown to brown-gray macules start in the middle area of the trunk and then spread to proximal areas of the limbs. Histopathology reveals pigmentation of the basal layer, few melanophages, and mild perivascular inflammatory infiltrate. 9 Ashy dermatosis/erythema dyschromicum perstans 2, 8, 9, 44 Present on the trunk and limbs. Macules are slate gray and may present with an erythematous firm, evanescent, string-like halo. Histopathology reveals epidermal vacuolization, deep pigmentary incontinence, and, characteristically, mild perivascular inflammatory infiltrates are found. 2, 8, 9, 44 Riehl's melanosis/pigmented contact dermatitis 2, 9, 44 A correlation with clinical history of contactants and positive patch testing is necessary. This dermatosis has been rarely described, and its origin is still unclear. History of hydroquinone use at high concentration for a prolonged period, most commonly on the face. Usually does not affect neck and flexural areas. Dermoscopy aids in its diagnosis; biopsy is confirmatory. 44 Hori nevus 9 Bluish-gray or dark brown 2-5 mm macules caused by dermal melanocytes affecting the cheeks, temples, or forehead. Biopsy confirms diagnosis. 9 Fixed drug reaction 9 Round, initially erythematous macules affecting face and genitals. History of medication intake prior to onset. Dark brown to light brown pigmentation on the face, rarely affecting arms, neck, and upper trunk. 44 Postinflammatory pigmentation 9 Previous history of dermatosis which leaves pigmentation as it subsides. Pathogenesis Associated with lichen planus. Prominent lichenoid response. 1, 7 Minor lichenoid response with centrifugal distribution. 8, 9 Clinical presentation Violaceous, gray and brown macules. Photoexposed and flexural areas. Frequent pruritus. [1] [2] [3] Gray-blue macules with or without raised erythematous borders. Photoexposed areas and trunk. Infrequent pruritus. 8, 9 Histopathology Prominent lichenoid features throughout the entire lesion. Frequent band-like lichenoid infiltrate and pronounced vacuolar degeneration of the epidermal basal cell layer. [1] [2] [3] Lichenoid features within the lesional peripheral active border and sparse in its center. Prominent perivascular infiltrate, as well as numerous melanophages. 8, 9 Treatment Partial response to topical and oral steroids, as well as other immunomodulators. [1] [2] [3] Absence or low response to topical/oral steroids. Partial response to certain immunomodulators such as tacrolimus and clofazimine.
8,9 Treatment of comorbidities 3, 34, 36 Avoid scarring alopecia in FFA, detect and treat endocrinopathies (DM2, hypothyroidism, and dyslipidemia), as well as associated autoimmune disorders and hepatitis C virus-induced liver disease. 3, 34, 36 Medium-high potency topical corticosteroids 8, 11, 13, 16, 20, 21 Anti-inflammatory 11 Once or twice daily 11 Use with caution in flexural areas and face.
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It accelerates the healing process, mainly used in LPP-inversus. 50% improvement in 12 weeks has been reported. 3 Depigmenting agents such as: 4% hydroquinone, Kojic acid, modified Kligman's formula (tretinoin 0.025% to 0.05%, hydroquinone 4%, 0.1% dexamethasone) 28, 29, 34 Inhibition of melanogenesis Increased epidermal turnover 28 At bedtime or twice daily 28 Adjuvant treatment when used in conjunction with an anti-inflammatory treatment. 28, 29, 34 Q-switched laser (1064 nm Nd-YAG) 32 Melanin selective photothermolysis 32 Every 3 weeks up to 4 months. 32 Low-moderate efficacy, expensive; has been used with tacrolimus in active cases. 32 Oral corticosteroids 19, 45 Anti-inflammatory 
Differential diagnoses
Differential diagnoses are summarized in Table 1 . The main differential diagnosis is erythema dyschromicum perstans (EDP), "ashy dermatosis". LPP and EDP are considered distinct entities, since they present specific clinical-pathological features ( been recently reported as a promising therapy with a relatively better side effect profile. Treatments are summarized in Table 3 .
Currently, it is unknown if it is appropriate to maintain antiinflammatory treatment for a prolonged period of time to prevent relapses since this could be detrimental by altering the migration and phagocytic function of macrophages, prolonging pigmentary incontinence, and consequently perpetuating pigmentation. Although slow to respond, a combination of topical and systemic treatments, as well as the avoidance of recognized triggers, will improve pigmentation and the aesthetic appearance in the majority of patients with LPP, thereby improving their quality of life.
Conclusions
Although the pathogenesis and etiology of LPP and its variants are still unclear, various associated factors have been observed, some common in all types, and others particular to a specific variant. It is important to avoid these factors to prevent and arrest the inflammatory process that leads to longstanding pigmentation. It is important to identify associated comorbidities, such as frontal fibrosing alopecia, hepatitis C virus-induced liver disease, endocrine disorders, and autoimmune diseases, in order to avoid serious sequelae and complications. The goal of treatment is to halt the inflammatory reaction by means of a combination of topical and systemic agents in order to decrease pigmentation and improve aesthetic appearance and its related emotional stress, thus improving quality of life.
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